Bone Remodelling Markers in Rheumatoid Arthritis
Bone loss in rheumatoid arthritis (RA) patients results from chronic inflammation and can lead to osteoporosis and fractures. A few bone remodeling markers have been studied in RA witnessing bone formation (osteocalcin), serum aminoterminal propeptide of type I collagen (PINP), serum carboxyterminal...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2014/484280 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849308149341749248 |
|---|---|
| author | Patrice Fardellone Alice Séjourné Julien Paccou Vincent Goëb |
| author_facet | Patrice Fardellone Alice Séjourné Julien Paccou Vincent Goëb |
| author_sort | Patrice Fardellone |
| collection | DOAJ |
| description | Bone loss in rheumatoid arthritis (RA) patients results from chronic inflammation and can lead to osteoporosis and fractures. A few bone remodeling markers have been studied in RA witnessing bone formation (osteocalcin), serum aminoterminal propeptide of type I collagen (PINP), serum carboxyterminal propeptide of type I collagen (ICTP), bone alkaline phosphatase (BAP), osteocalcin (OC), and bone resorption: C-terminal telopeptide of type 1 collagen (I-CTX), N-terminal telopeptide of type 1 collagen (I-NTX), pyridinolines (DPD and PYD), and tartrate-resistant acid phosphatase (TRAP). Bone resorption can be seen either in periarticular bone (demineralization and erosion) or in the total skeleton (osteoporosis). Whatever the location, bone resorption results from activation of osteoclasts when the ratio between osteoprotegerin and receptor activator of nuclear factor kappa-B ligand (OPG/RANKL) is decreased under influence of various proinflammatory cytokines. Bone remodeling markers also allow physicians to evaluate the effect of drugs used in RA like biologic agents, which reduce inflammation and exert a protecting effect on bone. We will discuss in this review changes in bone markers remodeling in patients with RA treated with biologics. |
| format | Article |
| id | doaj-art-144aea99f6954a6ebddf486b088c6f77 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-144aea99f6954a6ebddf486b088c6f772025-08-20T03:54:33ZengWileyMediators of Inflammation0962-93511466-18612014-01-01201410.1155/2014/484280484280Bone Remodelling Markers in Rheumatoid ArthritisPatrice Fardellone0Alice Séjourné1Julien Paccou2Vincent Goëb3Department of Rheumatology, Hôpital Nord, Place Victor Pauchet, 80054 Amiens, FranceDepartment of Rheumatology, Hôpital Nord, Place Victor Pauchet, 80054 Amiens, FranceDepartment of Rheumatology, Hôpital Nord, Place Victor Pauchet, 80054 Amiens, FranceDepartment of Rheumatology, Hôpital Nord, Place Victor Pauchet, 80054 Amiens, FranceBone loss in rheumatoid arthritis (RA) patients results from chronic inflammation and can lead to osteoporosis and fractures. A few bone remodeling markers have been studied in RA witnessing bone formation (osteocalcin), serum aminoterminal propeptide of type I collagen (PINP), serum carboxyterminal propeptide of type I collagen (ICTP), bone alkaline phosphatase (BAP), osteocalcin (OC), and bone resorption: C-terminal telopeptide of type 1 collagen (I-CTX), N-terminal telopeptide of type 1 collagen (I-NTX), pyridinolines (DPD and PYD), and tartrate-resistant acid phosphatase (TRAP). Bone resorption can be seen either in periarticular bone (demineralization and erosion) or in the total skeleton (osteoporosis). Whatever the location, bone resorption results from activation of osteoclasts when the ratio between osteoprotegerin and receptor activator of nuclear factor kappa-B ligand (OPG/RANKL) is decreased under influence of various proinflammatory cytokines. Bone remodeling markers also allow physicians to evaluate the effect of drugs used in RA like biologic agents, which reduce inflammation and exert a protecting effect on bone. We will discuss in this review changes in bone markers remodeling in patients with RA treated with biologics.http://dx.doi.org/10.1155/2014/484280 |
| spellingShingle | Patrice Fardellone Alice Séjourné Julien Paccou Vincent Goëb Bone Remodelling Markers in Rheumatoid Arthritis Mediators of Inflammation |
| title | Bone Remodelling Markers in Rheumatoid Arthritis |
| title_full | Bone Remodelling Markers in Rheumatoid Arthritis |
| title_fullStr | Bone Remodelling Markers in Rheumatoid Arthritis |
| title_full_unstemmed | Bone Remodelling Markers in Rheumatoid Arthritis |
| title_short | Bone Remodelling Markers in Rheumatoid Arthritis |
| title_sort | bone remodelling markers in rheumatoid arthritis |
| url | http://dx.doi.org/10.1155/2014/484280 |
| work_keys_str_mv | AT patricefardellone boneremodellingmarkersinrheumatoidarthritis AT alicesejourne boneremodellingmarkersinrheumatoidarthritis AT julienpaccou boneremodellingmarkersinrheumatoidarthritis AT vincentgoeb boneremodellingmarkersinrheumatoidarthritis |